T. Rowe Price Associates
IGC icon

T. Rowe Price Associates’s IGC Pharma IGC Stock Holding History

T. Rowe Price Associates’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-43,000
Closed -$71K – 2961
2021
Q2 		$71K Hold
43,000
– – ﹤0.01% 2876
2021
Q1 		$77K Buy
+43,000
New +$78.1K ﹤0.01% 2799

Other funds holding IGC

IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates's IGC Position: Q3 2021 in Review

T. Rowe Price Associates sold out of IGC Pharma (IGC) in Q3 2021, closing a stake of 43,000 shares — an estimated $71K sold.

T. Rowe Price Associates first reported a position in IGC in Q1 2021 and held it in 2 quarters. The position peaked at $77K in Q1 2021. 32 funds tracked by Wall St. Rank hold IGC as of Q3 2021.

  • T. Rowe Price Associates reported no remaining IGC Pharma position as of Q3 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 43,000 IGC Pharma shares in Q3 2021, an estimated $71K.
  • T. Rowe Price Associates first reported a position in IGC Pharma in Q1 2021 and held it in 2 quarters.
  • T. Rowe Price Associates's IGC Pharma position peaked at $77K in Q1 2021.
  • 32 funds tracked by Wall St. Rank held IGC Pharma as of Q3 2021.

Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.